Novo Nordisk A/S (0QIU.L)
| Chiusura precedente | N/D |
| Rendimento dall'inizio dell'anno (YTD) | N/D |
| Coefficiente di spesa (netto) | N/D |
| Categoria | N/D |
| Ultimo guadagno in conto di capitale | N/D |
| Rating di MorningStar | N/D |
| Rating di Morningstar (rischio) | N/D |
| Rating di sostenibilità |
| Attività nette | N/D |
| Beta (5 anni mensile) | N/D |
| Rendimento | N/D |
| Rendimento medio 5a | N/D |
| Turnover portafoglio titoli | N/D |
| Ultimo dividendo | N/D |
| Media per la categoria | N/D |
| Data di inizio disponibilità | N/D |
- GlobeNewswire
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 17 January 2022 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period
- GlobeNewswire
Novo Nordisk announces settlement of securities lawsuit in Denmark
Bagsværd, Denmark, 14 January 2022 – Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability, wrongdoing or responsibility by Novo Nordisk and no payment will be made by Novo Nordisk to the plaintiffs. The lawsuit was filed by a number of shareholders and alleged that Novo Nordisk had made misleading statements and did not make appropriate disclosures regarding its sales of insulin products
- GlobeNewswire
Novo Nordisk announces supply challenges for Wegovy® in the US
Bagsværd, Denmark, 17 December 2021 – Novo Nordisk today announced that a contract manufacturer filling syringes for Wegovy® pens for the US market has temporarily stopped deliveries and manufacturing following issues with Good Manufacturing Practices. As a consequence, Novo Nordisk does not expect to be able to meet demand in the US in the first half of 2022 and few new patients are expected to be able to initiate treatment. The priority for Novo Nordisk is patients who have already initiated t
